[{"id":"aa0ea678-0fd7-41d5-9cac-558568133e0c","acronym":"EBVision","url":"https://clinicaltrials.gov/study/NCT04554914","created_at":"2021-01-18T21:46:31.475Z","updated_at":"2025-02-25T15:11:41.557Z","phase":"Phase 2","brief_title":"A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases","source_id_and_acronym":"NCT04554914 - EBVision","lead_sponsor":"Atara Biotherapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tab-cel (tabelecleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"}]